Carefusion report “At the 41st Annual Conference of the Association for Professionals in Infection Control and Epidemiology (APIC), CareFusion (NYSE:CFN), a leading global medical technology company, will launch three new products that are designed to help reduce surface contamination or the presence of microorganisms that can potentially cause infections during hospital stays and procedures.”
Carefusion product launch includes the ChloraShield® IV dressing http://ctt.ec/No_e5+ @ivteam #ivteam
One of the products Carefusion report upon is “The ChloraShield® IV dressing with chlorhexidine gluconate (CHG) antimicrobial is a flexible and breathable dressing, that enhances patient care during vascular access procedures. The dressing features BeneHold™ CHG, an innovative adhesive technology from Vancive Medical Technologies™, an Avery Dennison business, which comfortably secures the dressing to the skin, absorbs fluid and protects the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth. ChloraShield dressings are designed to be easy for clinicians to apply and remove, and comfortable for patients to wear. CareFusion is the exclusive distributor of the dressing in North America.”
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.